A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
A Phase 1 Double-Blind, Double-Dummy, Parallel-Group, Randomized, Positive Control Study Using fMRI to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users
Sponsor: Nektar Therapeutics
Terminated
Sponsor Decision
This PHASE1 trial investigates Moderate to Severe Chronic Pain and is currently terminated or withdrawn. Nektar Therapeutics leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1
▶ Show 7 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Terminated PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Nov 2019 [monthly]
Recruiting PHASE1
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nektar Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .